Although the association of partnership concurrency and HIV prevalence has been studied in sub-Saharan settings, the impact of concurrency on HIV transmission has not. We investigated the association between concurrency and HIV serodiscordance in 142 ongoing marital and nonmarital relationships in which both partners were traced and tested for HIV. Our results suggest that multiple concurrent partnerships significantly increase exposure to HIV infection in the population of Likoma (Malawi). We highlight the potential role of behavioral interventions addressing partnership concurrency for HIV prevention.
Mathematical models suggest that partnership concurrency may significantly increase rates of HIV transmission within a population [1] . Transmission is amplified because concurrent partnerships immediately expose multiple partners to the risk of HIV infection, thereby creating potentially large sexual networks through which HIV can circulate extensively. Shelton [2] has recently suggested that such multiple concurrent partnerships (MCPs) may thus be the 'key driver' of generalized HIV epidemics affecting southern African countries. Large-scale behavioral interventions addressing this pattern of sexual mixing are currently being advocated and rolled-out [3] .
In US settings, researchers have used partner tracing designs (i.e. designs in which the partners of an index case are traced and their disease status is ascertained) to show that the odds of transmitting sexually transmitting infections were significantly higher among index cases with MCP [4, 5] . In sub-Saharan settings, several studies have established the high prevalence of MCP in countries affected by generalized HIV epidemics [6] . However, the role of MCP in the transmission of HIV has not yet been examined with empiric data from HIV-infected individuals. This is the case because sexual behavior surveys conducted in sub-Saharan populations have not been based on partner-tracing designs (e.g. DHS). Such individual-centered studies only allow ascertaining the association between concurrency and HIV acquisition, not transmission [7] . In this study, we use unique data from a sexual network study [8] to test whether MCPs are more likely to be HIV-serodiscordant than serially monogamous partnerships.
The Likoma Network Study (LNS) conducted a sexual network survey with 923 respondents in seven villages of Likoma Island, in the northern region of Lake Malawi [8, 9] . Respondents were asked to identify up to five of their most recent sexual partners during an audio computer-assisted self-interview [10] . The sexual partners identified were then traced in rosters of island residents and all data were linked. The HIV status of consenting respondents was ascertained using two rapid tests (Determine and Unigold) by a team of local health workers. In total, we tested 597 of the 923 survey respondents, and we identified 48 cases of HIV infection (HIV prevalence ¼ 8%). As a result of this design, we can establish the HIV status of both sexual partners in a subsample of the relationships identified during the survey. We define as concurrent any ongoing sexual relationship in which at least one of the two partners had another partner at the time of the survey. We define as serial any ongoing sexual relationship in which neither partners had any other partner at the time of the survey. Our analyses first examine the characteristics of sexual relationships in which both partners were tested for HIV infection. We then describe the association between partnership concurrency and HIV serodiscordance among this subsample of sexual relationships.
During the survey, respondents reported 776 sexual relationships defining 604 unique ongoing sexual relationships (some relationships were reported by both partners). Figure 1 (a) describes the attrition at different stages of the linking process. We ascertained the sexual behaviors of both partners in 401 relationships (66.4%). Two hundred and fifty-one (63%) relationships in which both partners were interviewed were concurrent. One hundred and forty-two relationships involved partners who were both tested for HIV infection during the survey (35%). Concurrent relationships were significantly less likely to involve two partners who were both tested during the LNS. Fifty-seven of the 251 concurrent relationships (22.7%) involved two partners who were both tested during the survey. On the contrary, 85 of the 150 serial relationships (56.7%) involved partners who were both tested during the survey (P < 0.001).
Among the relationships in which both partners were tested for HIV infection, 133 (93.7%) involved two partners who were HIV-negative according to our testing protocol, and 3 (2.1%) relationships involved two partners who were HIV-positive. Six (4.2%) relationships were serodiscordant (i.e. involved one partner infected with HIV and one susceptible partner). Patterns of HIV serodiscordance, however, varied between concurrent and serially monogamous relationships (Fig. 1b, c ). Whereas only one serial relationship was serodiscordant (1.2%), this was the case for five (8.8%) concurrent relationships. Three (3.5%) serial relationships were HIVpositive seroconcordant, whereas no concurrent relationships were found to be so. These differences were significant at the P ¼ 0.02 level according to Fisher's exact test.
Our findings thus support previous proposals derived from mathematical models suggesting that partnership concurrency may significantly increase the risk of HIV transmission in sub-Saharan populations. Our study, however, has important limitations. First of all, the small sample sizes limit inferences about the association of partnership concurrency and HIV serodiscordance in sexual partnerships. For example, our data do not allow the identification of whether the relative risk of transmission associated with concurrent partnerships varies by sex or age of the index case. Second, a high proportion of concurrent partnerships traced during our study involved partners whose HIV status was not ascertained by the research team. This sample selection bias may limit the validity of our inferences regarding the association of partnership concurrency and HIV serodiscordance [7] . Third, our data do not allow individuals to be classified as 'transmitters' or 'receivers' of infection. This limitation stems from the fact that our data are cross-sectional and the biomarkers of HIV infection that we used were limited to the detection of HIV antibodies (and thus did not allow the identification of recent acute HIV infection). Studies that have estimated precisely the impact of concurrency on the transmission of a pathogen in a population were either based on prospective research designs [4] or were able to classify connected cases of a disease by stage of disease progression [5] .
Despite these limitations, however, the design of this study (based on partner tracing) enables us for the first time to identify the increased risk of HIV transmission that may be associated with concurrent relationships. Building on this unique feature, our study indicates that behavioral change interventions addressing patterns of partnership concurrency may have a significant impact on the incidence of HIV in sub-Saharan populations affected by generalized HIVepidemics. Further studies integrating partner tracing and longitudinal follow-up are needed to confirm our findings, and adequately design and target behavioral change interventions. The best management strategy for HIV patients who fail to respond to first-line therapy for Pneumocystis jirovecii pneumonia is currently unclear. We identified all patients who were treated with trimetrexate and folinic acid who failed 7 or more days of cotrimoxazole, clindamycin-primaquine or dapsone-trimethoprim between 1996 and 2006. Trimetrexate was tolerated in 100% of cases with no treatment termination secondary to adverse drug reactions. Despite severe disease, 71% of patients were alive after 12 weeks.
Cotrimoxazole [trimethoprim-sulfamethoxazole (TMP-SMZ)] is the first-line therapeutic agent of choice for treatment of Pneumocystis jirovecii pneumonia (PCP) [1] . TMP-SMZ is associated with a high incidence of adverse drug reactions, resulting in intolerance in up to 50% of patients [2] . In addition, 9-42% of patients fail to respond to first-line therapy [3, 4] . Switching to second-line and third-line PCP regimens is common, yet the evidence base informing these decisions is limited.
Trimetrexate (TMTX), like TMP-SMZ, is a potent inhibitor of dihydrofolate reductase, licensed for the treatment of PCP [5] . TMTX and folinic acid are associated with a lower incidence of serious side effects than TMP-SMZ [6] . TMTX and folinic acid have been successfully used for the treatment and salvage of moderate-to-severe PCP but are inferior to TMP-SMZ as a first-line agent [6] .
We describe our experience using TMTX as a PCP salvage option for patients who fail to respond to 7 or more days of either first-line or second-line agents in a single centre. A retrospective case-finding strategy was employed to identify all HIV-1 seropositive patients with a confirmed microbiological diagnosis of PCP who were treated with TMTX and folinic acid between 1996 and 2006. First-line treatment for PCP during this period was with TMP-SMZ; second-line alternatives in case of TMP-SMZ toxicity included clindamycin-primaquine or dapsone-trimethoprim.
TMTX was administered intravenously at a dosage of 45 mg/m 2 once daily [7] . Folinic acid was given orally or intravenously at a dosage of 20 mg/m 2 four times a day and continued for 72 h after cessation of TMTX [7] .
The primary outcome was survival 28 days after starting TMTX. Failure to respond was determined by the treating physician and defined as increasing oxygen requirement or exhaustion necessitating ventilatory support. Patients were excluded if PCP was not confirmed or if TMTX was started within 7 days of commencing PCP treatment.
Sixteen patients were identified and complete data were available for 14, as presented in Table 1 . Ten patients were male, of whom nine were men who have sex with men. Twelve patients were newly diagnosed with HIV infection. The median CD4 cell count presentation was 27 cells/ml (range . Median Pao 2 was 5.6 kPa (range 3.5-11.1) and was below 9.3 kPa in 12 of 13 patients with a baseline result available.
TMTX salvage was started on a median day of 16 (range 8-34) after starting treatment for PCP and was administered for a median of 18 days (range 3-28). Five patients had documented adverse effects. Two patients developed anaemia (Hb ¼ 4.8 g/dl, 8.9 g/dl) treated with blood transfusion; one patient had documented neutropenia (<1 Â 10 9 /l), treated with an increased dose of folinic acid. Two patients developed rashes and one patient developed minor mouth ulceration. TMTX was not stopped because of toxicity in any patient.
Respiratory copathogens were isolated in five patients and responded to appropriate treatment ( Table 1) . All patients received corticosteroids. Highly-active antiretroviral therapy (HAART) was started during admission in 10 patients on a median day of 20 (range 10-45). There was no association between HAART initiation and survival. The other surviving patients were started on HAART after discharge. A total of 71% (10) patients were admitted to the ICU, at median day 4 of admission (range 1-39). Seventy percent of patients (7) were ventilated with noninvasive continuous positive airways pressure. Three patients later went on to be intubated; all died, two as a result of pneumothoraces.
Day 28 survival was 71% (10/14). Surviving patients remained alive at 12 weeks. The condition of two patients deteriorated after 21 days of TMTX therapy. One patient relapsed, was readmitted to ICU, started clindamycin-primaquine salvage therapy and died. The condition of other patient deteriorated. Mycobacterium avium intracellularae (MAI) infection was suspected. The patient was initiated on appropriate therapy and survived. MAI was later isolated from bronchoalveolar lavage culture.
To date, two systematic reviews have been published on the optimum management strategy for patients who fail to respond to first-line therapy for PCP [1, 8] . Both support the use of clindamycin-primaquine, but both include data from small studies (n ¼ 48) in which patients switched regimens because of intolerance (rather than failure) of primary therapy, despite the authors' intention to exclude such patients, making it hard to judge whether switching treatment in the absence of intolerability is justified.
An earlier study evaluating TMTX and folinic acid as salvage for patients who were intolerant or unresponsive to 7 or more days of TMP-SMX or pentamidine found similar results (n ¼ 16); 69% of patients survived to day 42 [9] . Subsequently, a larger (unpublished) case series summarized results from a programme that provided TMTX and folinic acid to patients who experienced treatment failure or dose-limiting toxicity with either TMP-SMX or pentamidine after 7 days or more and found only 41% patients responded (n ¼ 143) [10] . This series included all patients who received at least one dose of TMTX and thus its results are difficult to evaluate [11].
The above-mentioned is the first case series to characterize the use of TMTX and folinic acid in the context of adjunctive corticosteroids and HAART. These results are comparable to the 69% response seen with TMTX before the routine use of corticosteroids and similar to the 68% and 71% response estimated for second-line clindamycin-primaquine and TMP-SMX, respectively [1, 9] .
There are several limitations to this study. This retrospective series is small and data were not available for two cases. The subjective initiation and response criteria, determined by the attending physician, make the results susceptible to selection and observer bias. Nevertheless, these data are from a patient group with several features associated with poor outcome [1, 12] . TMTX and folinic acid are effective and well tolerated agents that should remain a valuable agent in salvage of PCP.
